Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial

Human Psychopharmacology

Volumn 23, Issue 3, 2008, Pages 211-216

  Chawla, Bharat ^a,b   Luxton Andrew, Heather ^a  

^a Peterborough Regional Health Centre   (Canada)

^b Ontario   (Canada)

Author keywords

Olanzapine; Orally disintegrating tablets; Schizophrenia; Weight loss

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DOSE RESPONSE; DRUG FORMULATION; FEMALE; HUMAN; MALE; MONOTHERAPY; OBESITY; OPEN STUDY; ORALLY DISINTEGRATING TABLET; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SIDE EFFECT; TABLET; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CHEMISTRY, PHARMACEUTICAL; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; OVERWEIGHT; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; WEIGHT LOSS;

EID: 42549153837     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.921     Document Type: Article

References (26)

1. Arranz B, San L, Duenas RM, et al. 2007. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol 22: 11-15.
2. Baptista T, Martinez J, Lacruz A, et al. 2006. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blinded placebo-controlled trial. Can J Psychiatry 51: 192-196.
3. Bergstrom RF, Mitchell M, Witcher J, et al. Rapid onset of absorption with olanzapine orally disintegrating tablets. Poster presented at the 157th Annual Meeting of the American Psychiatric Association, 1-6 May 2004. New York, USA.
4. Cahn W, van Haren EM, Hulshoffpol E, et al. 2006. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry 189: 381-382.
5. Crocq M-A, Guillon M-S, Bailey PE, Provost D. 2007. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. Eur Psychiatry 22: 453-454.
6. Deberdt W, Winokur A, Cavazzoni PA, et al. 2005. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 15: 13-21.
7. de Haan L, van Amelsvoort T, Rosien K, Linszen D. 2004. Weight loss after switching from conventional olanzapine tablets to orally disintegrating tablets. Psychopharmacology 175: 389-390.
8. Faulkner G, Cohn TA. 2006. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 51: 502-511.
9. Goudie AJ, Cooper GD, Halford JCG. 2005. Antipsychotic-induced weight gain. Diabetes Obes Metab 7: 478-487.
10. Henderson DC, Copeland PM, Daley TB, et al. 2005. A double-blind, placebo-controlled trial of sibulramine for olanzapine-associated weight gain. Am J Psychiatry 162: 954-962.
11. Hosojima H, Togo T, Odawara T, et al. 2006. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20: 75-79.
12. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. 2001. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 62 (suppl 2): 41-44.
13. Kojima M, Kangawa K. 2005. Ghrelin: structure and function. Physiol Rev 85: 495-522.
14. Lerner V, Libov I, Kanevsky M. 2003. High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenia patients, Intl J Psychiatry Med 33: 403-410.
15. Lieberman JA, Tollefson GD, Charles C, et al. 2005a. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62: 361-370.
16. Lieberman JA, Stroup TS, McEvoy JP, et al. 2005b. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
17. Markowitz JS, DeVane CL, Malcolm RJ, et al. 2006. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablets versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 46: 164-171.
18. Mitchell M, Riesenberg R, Bari MA, et al. 2006. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. Clin Ther 28: 881-892.
19. Murashita M, Kusumi I, Inoue T, et al. 2005. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30: 106-110.
20. Palik E, Birkas KD, Faludi G, Karádi I, Cseh K. 2005. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 68S1: S60-S64.
21. Qadri SF, Padala PR, Strunk JC, Boust SJ. 2006. High-dose olanzapine orally disintegrating tablets for treatment resistant psychosis. Prim Care Companion J Clin Psychiatry 8(4): 244-245.
22. Rossler W, Salize HJ, van Os J, Riecher-Rössler A. 2005, Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15: 399-409.
23. Stip E, Anselmo K, Wolfe M, Lessard C, Landry P. 2006. Long-term treatment with atypical antipsychotics and risk of weight gain. Drug Saf 29(6): 550-552.
24. Stroup TS, Lieberman JA, McEvoy JP, et al. 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163: 611-622.
25. Thompson PM, Vidal C, Giedd JN, et al. 2001. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 98(20): 11650-11655.
26. Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld Hamm B, Stern R. 2003. A Program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 54: 1155-1157.